ICICI Direct is bullish on Narayana Hrudayalaya has recommended buy rating on the stock with a target price of Rs 250 in its research report dated February 06, 2019.
ICICI Direct's research report on Narayana Hrudayalaya
Q3FY19 results were a mixed bag with revenues and EBITDA above I-direct estimates while net profit was lower than I-direct estimates due to higher depreciation and tax rate • Revenues grew 32.2% YoY to Rs 732 crore (I-direct estimate: Rs 713 crore) mainly due to consolidation of Health City Cayman Islands (Cayman)and ramp up in new hospitals • EBITDA margins improved 136 bps YoY to 10.6% (I-direct estimate: 10.1%) mainly due to lower other expenditure. EBITDA grew 51.5% YoY to Rs 78.0 crore (I-direct estimate: Rs 71.8 crore)• Net profit declined 9.7% YoY to Rs 12.7 crore (I-direct estimates of net profit: Rs 15.2 crore). The delta vis-a-vis EBITDA was due to higher interest cost and tax rate (46.3% vs. 42.2% in Q3FY18).
However, we remain positive on the stock as we believe the long term prospects remain intact on the back of asset-right model and affordability philosophy. We arrive at an SOTP target price of Rs 250 by valuing the matured hospitals and Cayman Islands at 8x of FY21E EV/EBITDA and other hospitals & other businesses at 1x FY21E EV/sales.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .